

PATTERNS OF AUTOIMMUNITY AND SUBSEQUENT CHRONIC LYMPHOCYTIC LEUKEMIA IN NORDIC COUNTRIES

Short title: Autoimmunity and CLL

Scientific heading: Neoplasia

Ola Landgren¹, Eric A. Engels¹, Neil E. Caporaso¹, Gloria Gridley¹,
Lene Mellemkjaer², Kari Hemminki^{3,4}, Martha S. Linet¹, Lynn R. Goldin¹

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

² Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark

³ Department of Biosciences at Novum, Karolinska Institute, Stockholm, Sweden

⁴ Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany

Address for correspondence: Ola Landgren, MD, PhD, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Bldg. EPS/Room 7110, Bethesda, MD 20892-7236; Phone: (301) 496-5786; Fax: (301) 402-4489; E-mail: landgreo@mail.nih.gov

Keywords: Chronic lymphocytic leukemia, susceptibility, etiology, pathogenesis, autoimmune, familial

Author Contributions: O Landgren, EA Engels, MS Linet, and LR Goldin designed the study. MS Linet, G Gridley, LR Goldin, L Mellemkjaer, and K Hemminki obtained data. O Landgren and EA Engels analyzed data. O Landgren, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, and Goldin LR were involved in the interpretation of the results. O Landgren initiated this work and wrote the report. All authors read, gave comments, and approved the final version of the manuscript. O Landgren, E Engels, and LR Goldin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ABSTRACT

A population-based case-control study was conducted to evaluate risk of developing chronic lymphocytic leukemia (CLL) associated with personal and/or family history of autoimmune and related diseases. Data were obtained for all (n=7,764) CLL cases diagnosed in Sweden and Denmark over a 40-year period and with linkable relatives, 16,658 matched controls, and first-degree relatives of cases (n=17,991) and controls (n=39,388). Odds ratios (ORs) were calculated to quantify risk of CLL in relation to personal/family history of 32 autoimmune and related disorders. The risk of CLL was significantly increased among subjects with a personal history of pernicious anemia (OR=1.94;1.18-3.18), mainly in the 0-1 years latency period. A significantly decreased risk of CLL was found among individuals with a personal history of chronic rheumatic heart disease (OR=0.55;0.33-0.93), particularly persons with a long latency (10+ years) between the two conditions. We found no association between personal or familial occurrence of other autoimmune or related disorders and CLL. If our results are confirmed, mechanistic studies examining how pernicious anemia might promote increased occurrence of CLL and how chronic rheumatic heart disease protects against CLL, perhaps related to long-term antibiotics use, may provide insights to the as yet unknown etiology of CLL.

INTRODUCTION

B-cell chronic lymphocytic leukemia (B-CLL) is a neoplastic disease characterized by the accumulation of small, mature-appearing lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL accounts for 30% of all leukemia and is the most common form of leukemia among older adults in Western countries. Data from the United States Surveillance, Epidemiology, and End Results (SEER) Registry estimate the U.S. incidence in the period from 1996 to 2000 to be 3.7 per 100 000 with a median age at diagnosis of 72 years ¹. Incidence rates in men are nearly twice as high as in women. Although advanced age, Caucasian race, and family history of certain hematologic malignancies are recognized risk factors, the etiology of CLL is mostly unknown. Case-control studies have evaluated diverse environmental and occupational exposures such as pesticides, viruses, ionizing radiation, and non-ionizing power-frequency magnetic fields, but have not found consistent associations ². Family history of CLL or other hematolymphoproliferative cancers, on the other hand, have consistently been identified as a risk factor for CLL ³⁻⁹.

Autoimmune phenomena are a well-known complication of CLL ¹⁰⁻¹³, almost as a counterpoint to the frequent and profound hypogammaglobulinemia that accompanies the disease ¹⁴. The possible relationship of autoimmune disorders as risk factors for CLL has been evaluated based on the nature and functioning of lymphocytes, results of experimental studies, clinical reports, and limited data from epidemiological studies. However, there are inconsistencies in the limited literature on this topic and it remains yet unclear whether or not autoimmune or related disorders predispose toward increased risk of CLL ¹⁵⁻¹⁸. Interestingly, there are also reports of familial aggregation of malignant lymphomas together with autoimmune diseases but to our

knowledge there is very limited information on familial occurrence of CLL and autoimmune disorders .

In the first investigation to evaluate both personal and familial occurrence of autoimmune and related disorders, we conducted a population-based comprehensive assessment of hospital discharge records for 32 autoimmune and related conditions among all (N=7,764) CLL cases, more than 16,000 frequency-matched controls and over 56,000 of their first-degree relatives in Sweden and Denmark over a 40-year-period.

METHODS

Cases, controls and first-degree relatives

The Swedish Cancer Register has been in operation since 1958 with near complete coverage^{23,24}. The Swedish Multi-generation Register²⁵ includes information on parent-offspring relations for all Swedish citizens born in 1932 or later. Through iterated linkage using this register, parents, siblings, and offspring of individuals born 1932 or later can be identified. The Swedish Multi-generation Register has been merged with the Swedish Cancer Registry (all cancers diagnosed 1958-1998) to create the Family-Cancer Database which has been described in detail elsewhere^{3,26,27}. In the Family-Cancer Database, all individuals registered with a first primary diagnosis of CLL (International Classification of Diseases [ICD] 7th Revision code 204.1) between 1958 and 1998 were identified as cases. For each case, information on date of birth, date of diagnosis of CLL, and sex was collected. In addition, for each case, two malignancy-free controls who matched the case in terms of gender, year of birth, and county of residence in the year of the index patient's CLL diagnosis were chosen from the database. Matching by county of residence controlled for regional variability over time in cancer reporting. Case patients and controls with no relatives identified from the linkage were removed from the dataset, and duplicate controls also were removed. Thus, using the Family-Cancer Database we identified all reported Swedish CLL cases, matched controls, and their first-degree relatives.

A similar database of case patients with CLL, controls, and relatives was created using the Danish Cancer Registry and the Danish Central Population Registry (CPR)^{3,28}. The Danish Cancer Registry became a nationwide registry in 1943, but we limited the selection of CLL cases to those diagnosed after April 1, 1968, because patients with malignant disease who died before that date could not be linked to the CPR. The CPR contains links of offspring to parents (and

vice versa) starting with all children born in 1968 as well as linkages (also starting in 1968) among family members living at the same address. Thus, all individuals with a first primary CLL diagnosed between 1968 and 1997 were selected from the Danish Cancer Registry. Four malignancy-free controls per case were chosen from the CPR. All first-degree relatives were identified by linking to the CPR. Case patients and controls with no relatives identified from the linkage were removed from the study, and duplicate controls also were removed. This resulted in fewer than four controls per case patient in the final sample. All cancer diagnoses were ascertained for relatives by linking them to the cancer registry.

Approval was obtained from the NIH institutional review board for these studies. Informed consent was waived because we had no contact with study subjects.

Autoimmune conditions

All Swedish individuals were linked with the Swedish Inpatient Register 1964-2000, which contains information on discharges from inpatient care (coded according to ICD 7th to 10th Revisions) with a population-based coverage that, county by county, encompassed 50% of Sweden in the mid 1970s and 100% since 1987. All Danish individuals were linked with the Danish Inpatient (1977-1997) and Outpatient (1994-1997) Register in a similar way. Through this linkage, we collected information on discharges listing any of the following coded autoimmune and related conditions ²⁹: polymyositis/dermatomyositis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis, Addison's disease, amyotrophic lateral sclerosis, autoimmune hemolytic anemia, chronic rheumatic heart diseases, discoid lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, immune thrombocytopenic purpura, insulin-dependent diabetes (see below), localized scleroderma,

lupoid hepatitis, multiple sclerosis, myasthenia gravis, pernicious anemia, polyarteritis nodosa, primary biliary cirrhosis, Wegener's granulomatosis, ankylosing spondylitis, Behcet's disease, chorea minor, Crohn's disease, polymyalgia rheumatica, psoriasis, Reiter's disease, rheumatic fever, sarcoidosis, and ulcerative colitis. There is no code that unambiguously delineates diabetes mellitus type I from type II in the hospital discharge listing for either Sweden or Denmark. Subjects with diabetes mellitus diagnosed before 30 years of age were designated as *diabetes mellitus type I* in accord with a previous study²⁹.

Statistical analysis

We calculated odds ratios (OR) as measures of relative risks using unconditional logistic regression. We assessed the association between personal history of defined autoimmune conditions and CLL among cases and controls. ORs were adjusted for age, gender, calendar period, and region using logistic regression. When the number of subjects with the autoimmune condition in CLL cases or controls was zero, we instead present unadjusted *P*-values derived using Fisher's exact test. Using logistic regression, we examined the relationship between CLL risk and latency, i.e., time from first inpatient discharge listing a defined autoimmune condition (0-1, 2-4, 5-9, 10 or more years). Since risk of autoimmune and related conditions may differ depending on the age of diagnosis at CLL, we separately analyzed the relationship between autoimmune and related conditions and early diagnosis (<50 years), mid-life diagnosis (50-70 years), and late diagnosis (>70 years) CLL, respectively. We also stratified our analyses by gender. Similarly, to measure associations between CLL and a hospital discharge diagnosis of autoimmune or related conditions in one or more family members (denoted: *family history of*

autoimmune or related conditions), we used logistic regression, adjusting for age, gender, calendar period, and region as well as for personal history of that condition.

In order to test the robustness of these models in relation to potential variation in diagnostic procedures over time, sub-analyses stratified by calendar period (<1980 versus ≥ 1980) were conducted.

RESULTS

A total of 5,927 CLL cases, 11,796 matched controls, and corresponding relatives of cases (N=14,371) and controls (N=28,943) were included in the Swedish dataset. In the Danish dataset, we included 1,837 CLL cases, 4,862 matched controls, and corresponding relatives of cases (N=3,620) and controls (N=10,445). As expected, due to the relatively high median age at CLL diagnosis and given inherent database truncations, the largest proportion of identified first-degree relatives were offspring (Table 1). The total number of cases versus controls with a personal history of autoimmune and related conditions was 280 versus 472, respectively. Among affected cases, the distribution of autoimmune and related conditions per individual was: 1 conditions (94%), 2 conditions (5%), and 3 conditions (1%); and for controls the corresponding numbers were 92%, 7%, and 1%.

We first examined risk of CLL in relation to personal history of autoimmune and related conditions (Table 2). Substantially increased risk for CLL was found among subjects with a history of autoimmune hemolytic anemia (OR=108.40, 95% CI 14.99-784), and an association with pernicious anemia was also significant (OR=1.94, 95% CI 1.18-3.18). The association with Sjögren's syndrome almost reached statistical significance (OR=3.96, 95% CI 0.99-15.85). Conversely, we found a significantly decreased risk for CLL among subjects with a personal history of rheumatic heart disease (OR=0.55, 95% CI 0.33-0.93). CLL was not related to personal history of other autoimmune or related disorders.

When analyses were stratified by time between first hospitalization for autoimmune and related conditions and subsequent CLL diagnosis we found that 48 of the 54 cases of autoimmune hemolytic anemia had hospital discharge diagnoses of this disorder a few weeks to months before the diagnosis of CLL. Similarly, significant excess of CLL were observed within

one year of hospital discharge for patients with pernicious anemia (OR=8.37, 95% CI 3.14-22.35), based on 20 cases versus 5 controls, and Sjögren's syndrome ($P=0.032$), based on 3 cases versus 0 controls. For chronic rheumatic heart disease, risk of CLL did not differ significantly from unity until 10 or more years after discharge diagnosis of chronic rheumatic heart disease when a significantly reduced risk of CLL was observed (OR=0.30, 95% CI 0.10-0.84).

When analyses were stratified by age at CLL diagnosis, in total there were 11, 129, and 140 subjects with autoimmune or related conditions out of 681, 4,084, and 2,999 CLL cases who were ages <50 years, 51-70 years, and >70 years at diagnosis. For pernicious anemia and Sjögren's syndrome, this was reflected in equally elevated, although imprecise, risk estimates in the latter two age groups (data not shown). For autoimmune hemolytic anemia, the risk estimates and numbers in the mid-life and the late onset CLL groups were: (OR=53.31, 95% CI 7.23-393; n=26 cases versus 1 control) and ($P<0.0001$; n=28 cases and 0 controls), respectively. For subjects with personal history of chronic rheumatic heart disease, decreased risk of CLL was only observed among those with CLL at age >70 years (OR=0.45, 95% CI 0.22-0.93; n=9 cases versus 39 controls).

When we stratified our analyses by gender the risk estimates were very similar for males and females, respectively (data not shown). When numbers permitted, we conducted sub-analyses stratified by calendar period (<1980 versus ≥ 1980) with similar findings (data not shown).

For family history, we found a significantly increased risk of CLL among subjects with a family history of amyotrophic lateral sclerosis ($P=0.032$); however the estimate was based on very few observations (Table 2). CLL was not related to family history of other conditions under

study. Subjects with single or multiple autoimmune or related conditions were not aggregated together in families, nor were they in families with more than one CLL case.

DISCUSSION

In our systematic evaluation of autoimmune conditions and CLL, an important negative observation was that we did not observe a generally increased risk of CLL following these conditions. Specifically, for 29 of 32 conditions under study we found no statistical association. None of the 32 autoimmune and related conditions under study showed *both* a positive personal *and* family history of the same disorder to be associated with a significantly increased risk of CLL. A very strong association was observed for personal history of autoimmune hemolytic anemia and subsequent CLL, primarily within one year of diagnosis of CLL. However, since autoimmune hemolytic anemia is a well-known complication of CLL^{13,30}, it is most likely that this association reflects reverse causality due to undetected CLL cases manifesting with autoimmune hemolytic anemia as the first symptom.

Likewise, we found no relationship between family history of autoimmune or related conditions in first-degree relatives and risk of subsequent CLL, for 31 of 32 conditions investigated. Risk of CLL was significantly increased among subjects whose first-degree relatives had a diagnosis of amyotrophic lateral sclerosis, based on 3 cases versus 0 controls. However, given the lack of specific prior hypothesis as well as the number of autoimmune and related conditions under study, we consider the relationship of amyotrophic lateral sclerosis in first-degree relatives with risk of CLL to be a chance finding. Our data thus provide no support for the hypothesis that genetic factors predisposing to autoimmune disorders also influence susceptibility to CLL.

An increased risk of CLL following autoimmune conditions has been suggested in some previous smaller case series¹⁵⁻¹⁷ but not in a case-control study including more than 300 CLL cases¹⁸. Also, one small study reported more autoimmune diseases among first-degree relatives

of CLL cases compared to relatives of controls ²². Our results therefore add substantially to and clarify the restricted literature on the topic of autoimmune conditions prior to CLL, because we had access to a substantially larger (N=7,764) population-based investigation and information on family history of autoimmune disease among first-degree relatives of cases and controls retrieved through nationwide record-linkage.

The observed almost 2-fold excess of CLL diagnosed within a year of hospital discharge for pernicious anemia could entirely be due to early diagnosis of asymptomatic CLL cases rather than etiologic in nature, or it could be a chance finding due to multiple comparisons. However, we recently found an excess of multiple myeloma ²⁹ and NHL (unpublished data) diagnosed within a short period of time after hospital discharge for pernicious anemia. The possible relationship between pernicious anemia and CLL, multiple myeloma, and NHL could also reflect early diagnosis. However, since pernicious anemia has been reported as a risk factor for CLL in some case reports ³¹ but not been observed to be a complication of CLL, it might as well be possible that the underlying pathogenic mechanisms of the association between pernicious anemia and hematolymphoproliferative cancers may include shared genetic, host and/or environmental susceptibility of the two conditions.

A completely unexpected finding was an almost 50 percent decreased risk of CLL among subjects with a history of chronic rheumatic heart disease. While this could be a chance association due to multiple comparisons, the patterns suggest that the finding should be followed-up. The observed protective effect was strongest among subjects >70 years and among those with more than 10 years of latency following hospitalization for rheumatic heart disease. We speculate that this could reflect the usage of long-term antibiotic prophylaxis which normally is given to patients with chronic rheumatic heart disease ³². Since CLL may be associated with

the occurrence of bacterial infections (34), it is possible that long-term prophylactic penicillin leads to decreased occurrence of bacterial infections resulting in a reduced number of secondary inflammations which lowers the risk of CLL ³³. We have also recently reported a 50 percent decreased risk of multiple myeloma among subjects with a previous personal history of chronic rheumatic heart disease ²⁹. Unfortunately, the information available in our database for both studies does not provide the detailed clinical data that would allow us to evaluate this hypothesis directly. Thus, these findings need to be tested in future epidemiological studies that include medical record validation of detailed clinical, diagnostic, prognostic, and treatment data.

In our study, we used a register-based case-control design, which minimized recall-bias, allowed us to evaluate risk according to age and gender, and provided a very large population-based sample. By including all CLL cases diagnosed in Sweden and Denmark during a 40-year period with one or more linkable relatives, we were able to conduct the largest study on autoimmunity and subsequent risk of CLL to date, with enough power to report convincingly null findings. Limitations include incomplete numbers of first-degree relatives of all cases and controls, lack of information on all potential confounders, lack of validation of the hospital discharge diagnoses of autoimmune and related conditions, and failure to capture those autoimmune diseases diagnosed in outpatient settings. However, because personal and family history of autoimmune and related disorders were assessed among matched controls using the same hospital discharge registries, under-diagnosis of autoimmune and related disorders in subjects or their first-degree relatives should be non-differential between cases and controls, and thus any bias should have been conservative, i.e., toward a null association ^{34,35}. Another limitation is the large number of tested autoimmune and related conditions which implies that one has to interpret detected associations with caution due to multiple comparisons.

Recent literature has described restricted V_H gene usage in CLL cells, suggesting that there might be a common antigen involved in CLL pathogenesis³⁶, and consistent with the established understanding that clonal V_H mutations seen in B-CLL cells are the product of a classical antigen-driven somatic hypermutation process³⁷⁻³⁹. Our findings fit within this framework and broadly suggest that the common antigens involved in the pathogenesis of CLL are less likely of auto-antigen type, and more likely represent extrinsic environment factors, speculatively of infectious origin.

In summary, personal and family history of autoimmune and related conditions was generally not associated with risk of CLL. The association patterns found with pernicious anemia and chronic rheumatic heart disease suggest avenues for future etiologic studies.

ACKNOWLEDGEMENTS

This research was supported by the Intramural Research Program of the NIH, NCI. The authors thank Ms. Emily Steplowski, Information Management Services, Silver Spring, MD, for important efforts in setting up this complex database, and Dr. B. J. Stone for her consultation in creating numerous variables.

REFERENCES

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
2. Sgambati MT, Linet MS, Devesa S. Chronic lymphocytic leukemia. Epidemiological, familial, and genetic aspects. Vol. 2nd ed. Basel, Switzerland: Marcel Dekker; 2001.
3. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. *Blood*. 2004;104:1850-1854.
4. Linet MS, Van Natta ML, Brookmeyer R, et al. Familial cancer history and chronic lymphocytic leukemia. A case-control study. *Am J Epidemiol*. 1989;130:655-664.
5. Cartwright RA, Bernard SM, Bird CC, et al. Chronic lymphocytic leukaemia: case control epidemiological study in Yorkshire. *Br J Cancer*. 1987;56:79-82.
6. Pottern LM, Linet M, Blair A, et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma. *Leuk Res*. 1991;15:305-314.
7. Radovanovic Z, Markovic-Denic L, Jankovic S. Cancer mortality of family members of patients with chronic lymphocytic leukemia. *Eur J Epidemiol*. 1994;10:211-213.
8. Capalbo S, Trerotoli P, Ciancio A, Battista C, Serio G, Liso V. Increased risk of lymphoproliferative disorders in relatives of patients with B-cell chronic lymphocytic leukemia: relevance of the degree of familial linkage. *Eur J Haematol*. 2000;65:114-117.
9. Cannon-Albright LA, Thomas A, Goldgar DE, et al. Familiality of cancer in Utah. *Cancer Res*. 1994;54:2378-2385.
10. Polliack A, Lugassy G. Autoimmunity and auto-immune syndromes associated with and preceding the development of lymphoproliferative disorders. *Leukemia*. 1992;6 Suppl 4:152-154.
11. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. *Ann Intern Med*. 1990;113:525-539.
12. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. *J Clin Pathol*. 1986;39:713-716.
13. Hamblin TJ. Autoimmune disease and its management in chronic lymphocytic leukemia. In: Cheson BD, ed. *Chronic lymphoid leukemias* (ed 2nd). New York: Marcel Dekker, Inc; 2001:435-458.
14. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. *Blood*. 2004;103:4389-4395.
15. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF, Jr. Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. *Cancer Causes Control*. 1993;4:361-368.
16. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. *Cancer Causes Control*. 1992;3:449-456.
17. Linet MS, Cartwright RA. Chronic lymphocytic leukemia: epidemiology and etiologic findings. *Nouv Rev Fr Hematol*. 1988;30:353-357.
18. Linet MS, McCaffrey LD, Humphrey RL, et al. Chronic lymphocytic leukemia and acquired disorders affecting the immune system: a case-control study. *J Natl Cancer Inst*. 1986;77:371-378.
19. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. *Arthritis Rheum*. 2003;48:963-970.

20. Mellemkjaer L, Alexander F, Olsen JH. Cancer among children of parents with autoimmune diseases. *Br J Cancer*. 2000;82:1353-1357.
21. Linet MS, McLaughlin JK, Harlow SD, Fraumeni JF. Family history of autoimmune disorders and cancer in multiple myeloma. *Int J Epidemiol*. 1988;17:512-513.
22. Conley CL, Misiti J, Laster AJ. Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. *Medicine (Baltimore)*. 1980;59:323-334.
23. Anonymous. Patientregistret 1987-1996: Kvalitet och innehåll (Swedish). Stockholm: EpC, National Board of Health and Welfare; 1998.
24. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. *Acta Radiol Oncol*. 1984;23:305-313.
25. Skarle A. Flergenerationsregistret. Stockholm: Statistics Sweden, Population Statistics; 2001.
26. Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P. The nation-wide Swedish family-cancer database--updated structure and familial rates. *Acta Oncol*. 2001;40:772-777.
27. Hemminki K, Vaittinen P. National database of familial cancer in Sweden. *Genet Epidemiol*. 1998;15:225-236.
28. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. *Cancer*. 2004;100:1902-1908.
29. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. *Int J Cancer*. 2005:Epub ahead of print.
30. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. *Blood*. 2000;95:2786-2792.
31. Parker AC, Bennett M. Pernicious anaemia and lymphoproliferative disease. *Scand J Haematol*. 1976;17:395-397.
32. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. *Lancet*. 2005;366:155-168.
33. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med*. 2005;352:804-815.
34. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. *J Natl Cancer Inst*. 2004;96:780-784.
35. Landgren O, Kerstann KF, Gridley G, et al. Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. *J Natl Cancer Inst*. 2005;97:543-544.
36. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-utilizing chronic lymphocytic leukemia independent of geographical origin and mutational status. *Blood*. 2005.
37. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. *Blood*. 2004;103:3490-3495.
38. Kienle D, Benner A, Krober A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. *Blood*. 2005.
39. Capello D, Guarini A, Berra E, et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. *Leukemia*. 2004;18:1941-1947.

TABLE 1. Characteristics of CLL cases and controls

Variable	Sweden		Denmark	
	Cases	Controls	Cases	Controls
Total number	5,927	11,796	1,837	4,862
Age in years at CLL diagnosis, median (interquartile range)	69 (61-76)		62 (54-69)	
Age group at CLL diagnosis, n (%)				
Young-adult onset CLL (≤ 50 years)	380 (6)	761 (7)	301 (16)	1,016 (21)
Mid-life onset CLL (51-70 years)	2,904 (49)	5,786 (49)	1,180 (64)	3,208 (66)
Late onset CLL (> 70 years)	2,643 (45)	5,249 (44)	356 (20)	638 (13)
Gender, n (%)				
Male	3,854 (65)	7,660 (65)	1,287 (70)	3,403 (70)
Female	2,073 (35)	4,136 (35)	550 (30)	1,459 (30)
Calendar year at CLL diagnosis, median (interquartile range)	1985 (1977-1993)		1990 (1984-1994)	
First-degree relatives, n (mean number per proband)				
Parents	1,101 (0.2)	2,200 (0.2)	121 (0.1)	414 (0.1)
Siblings	930 (0.2)	1,870 (0.2)	80 (0.1)	218 (0.1)
Offspring	12,340 (2.1)	24,873 (2.1)	3,419 (1.9)	9,813 (2.1)

Abbreviations: CLL = Chronic lymphocytic leukemia

TABLE 2. Association between chronic lymphocytic leukemia (CLL) in relation to personal and family history of autoimmune conditions

Autoimmune condition	Personal history					Family history				
	ca	co	OR	95% Low	95% High	ca	co	OR	95% Low	95% High
Autoantibodies detectable										
Systemic involvement										
Polymyositis/dermatomyositis	17	22	1.58	0.84	2.99	15	36	0.87	0.47	1.59
Rheumatoid arthritis	68	136	1.03	0.76	1.38	49	129	0.81	0.58	1.13
Sjögren's syndrome	6	3	3.96	0.99	15.85	1	3	0.71	0.07	6.81
Systemic lupus erythematosus	3	8	0.83	0.22	3.16	13	23	1.22	0.62	2.42
Systemic sclerosis	7	5	2.75	0.87	8.69	5	6	1.89	0.58	6.23
Organ involvement										
Addison's disease	0	8	0	(P=0.062)		4	4	2.25	0.56	9.03
Amyotrophic lateral sclerosis	2	7	0.54	0.11	2.61	<u>3</u>	<u>0</u>	<u>Inf.</u>	(P=0.032)	
Autoimmune hemolytic anemia	54	1	<u>108.40</u>	<u>14.99</u>	<u>784</u>	1	5	0.42	0.05	3.58
Chronic rheumatic heart disease	18	67	<u>0.55</u>	<u>0.33</u>	<u>0.93</u>	14	23	1.44	0.74	2.81
Discoid lupus erythematosus	0	1	0	(P=1.00)		0	2	0	(P=1.00)	
Grave's disease	3	13	0.50	0.14	1.77	8	19	0.90	0.39	2.06
Hashimoto's thyroiditis	2	4	1.07	0.20	5.88	4	2	4.75	0.87	25.99
Immune thrombocytopenic purpura	5	5	2.16	0.62	7.51	0	8	0	(P=0.062)	
Insulin-dependent diabetes	0	0	-			12	17	1.80	0.86	3.78
Localized scleroderma	0	0	-			1	0	Inf.	(P=0.32)	
Lupoid hepatitis	0	0	-			0	0	-		
Multiple sclerosis	9	25	0.80	0.37	1.72	20	37	1.18	0.68	2.04
Myasthenia gravis	2	1	4.78	0.43	53.02	4	3	2.71	0.61	12.13
Pernicious anemia	31	32	<u>1.94</u>	<u>1.18</u>	<u>3.18</u>	9	18	1.21	0.54	2.70
Polyarteritis nodosa	1	1	1.93	0.12	30.91	0	3	0	(P=0.56)	
Primary biliary cirrhosis	1	5	0.42	0.05	3.62	2	3	1.38	0.23	8.31
Wegener's granulomatosis	0	2	0	(P=1.00)		0	3	0	(P=0.56)	
Autoantibodies not detectable										
Ankylosing spondylitis	6	9	1.41	0.50	3.98	11	13	1.71	0.76	3.82
Behcet's disease	0	0	-			0	0	-		
Chorea minor	0	0	-			0	0	-		
Crohn's disease	4	21	0.42	0.14	1.21	28	55	1.13	0.73	1.74
Polymyalgia rheumatica	22	42	1.06	0.63	1.79	11	24	1.08	0.53	2.21
Psoriasis	10	35	0.57	0.28	1.15	15	32	1.03	0.56	1.91
Reiter's disease	0	2	0	(P=1.00)		8	11	1.66	0.67	4.14
Rheumatic fever	3	9	0.66	0.18	2.43	7	18	0.84	0.35	2.02
Sarcoidosis	8	19	0.90	0.39	2.07	12	31	0.82	0.42	1.61
Ulcerative colitis	9	22	0.89	0.41	1.94	39	59	1.40	0.94	2.08

Abbreviations: ca = cases, co = controls; yrs = years; OR = odd ratio; CI = confidence interval; Inf. = infinity.

P-values (2-sided) based on the Fisher's exact test are given when cases or controls have zero individuals with the specified condition. ORs for personal history were adjusted for age, calendar time of CLL diagnosis, gender, and region. ORs for family history were adjusted for age, calendar time of CLL diagnosis, gender, region, and personal history of the same disorder. Underlined entries have P-values < .05.